Akari Therapeutics Stock News

NEW YORK and LONDON, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced new data showing that clinical outcomes in U.S. Army trauma patients correlate with complement activation, and that nomacopan significantly improves survival from 30% to 80% in a clinically relevant preclinical model of traumatic hemorrhage. A full data set is available at https://doi.org/10.22541/au.164423459.98723938/v1

ADRs End Higher; Akari Therapeutics, British American Tobacco Trades Actively MarketWatch

NEW YORK and LONDON, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune an

NEW YORK and LONDON, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and

Akari Therapeutics <> said the U.S. Food and Drug Administration ((FDA)) agreed to the clinical use of nomacopan derived from a next generation manufacturing process.Nomacopan,…

NEW YORK and LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and

The stock price of Akari Therapeutics PLC (NASDAQ: AKTX) fell by 9.21% in the most recent trading session. This is why it happened.

NEW YORK and LONDON, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to tr

Akari Therapeutics, Plc (NASDAQ:AKTX)s stock price crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $1.62 and traded as high as $1.64. Akari Therapeutics shares last traded at $1.54, with a volume of 75,065 shares traded. The company has a market cap of $73.30 million, []

NEW YORK and LONDON, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune an

NEW YORK and LONDON, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced its financial results for the third quarter of 2021 and recent clinical progress.

Data suggest potential therapeutic role for nomacopan in exacerbations in severe lung conditions such as COPD and COVID pneumonia Data suggest potential therapeutic role for nomacopan in exacerbations in severe lung conditions such as COPD and COVID pneumonia

Akari Therapeutics, Plc (NASDAQ:AKTX) was the recipient of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 15,700 shares, a drop of 74.4% from the October 31st total of 61,300 shares. Based on an average daily volume of 113,700 shares, the short-interest ratio is []

Akari Therapeutics, Plc (NASDAQ:AKTX) was the target of a large decline in short interest in November. As of November 15th, there was short interest totalling 15,700 shares, a decline of 74.4% from the October 31st total of 61,300 shares. Based on an average daily volume of 113,700 shares, the days-to-cover ratio is currently 0.1 days. []